| Browse All

Imunon, Inc. (IMNN)

Healthcare | Biotechnology | Lawrenceville, United States | NasdaqCM
3.10 USD +0.07 (2.310%) ⇧ (April 17, 2026, 4 p.m. EDT)
After hours: 3.18 +0.08 (2.581%) ⇧ (April 17, 2026, 5:23 p.m. EDT)

Short-term: ★★☆☆☆ | Long-term: ★☆☆☆☆ | Dividends: ☆☆☆☆☆
Hot Take | April 11, 2026, 3:03 p.m. EDT

IMNN is a biotechnology stock with significant volatility and negative fundamentals, including negative earnings and a high debt-to-equity ratio. The recent price history shows a downward trend with a recent dip to $2.92, which is near its 52-week low. While there are positive news headlines about clinical trial results and strategic restructuring, the stock's fundamentals are weak, and it lacks a dividend history. The forecasting model suggests a negative price direction, making it a risky short-term investment. For long-term investors, the stock's poor fundamentals and lack of dividends make it unsuitable. Overall, this stock is not recommended for either short-term or long-term investment.

Model Selection — Backtest MAE (log-scale, lower is better)
ModelMAE
AutoTheta ✓0.079602
AutoARIMA0.093482
AutoETS0.094709
MSTL0.096559

Forecast horizon: 45 days | Selected: AutoTheta

Forecast Reliability
Score 48%
H-stat 4.65
Ljung-Box p 0.000
Jarque-Bera p 0.891
Excess Kurtosis 0.32
Attribute Value
Sector Healthcare
Debt to Equity Ratio 14.285
Market Cap 12,160,568
Forward P/E -1.10
Beta 2.12
Previous Name Celsion Corporation
Website https://imunon.com

Info Dump

Attribute Value
52 Week Change -0.7329588
Address1 997 Lenox Drive
Address2 Suite 100
All Time High 1,897,032.9
All Time Low 2.52
Ask 3.9
Ask Size 2
Average Daily Volume10 Day 37,750
Average Daily Volume3 Month 89,022
Average Volume 89,022
Average Volume10Days 37,750
Beta 2.121
Bid 2.28
Bid Size 2
Book Value 2.065
City Lawrenceville
Compensation As Of Epoch Date 1,767,139,200
Country United States
Crypto Tradeable 0
Currency USD
Current Price 3.1
Current Ratio 2.319
Custom Price Alert Confidence HIGH
Date Short Interest 1,774,915,200
Day High 3.2
Day Low 3.04
Debt To Equity 14.285
Display Name Imunon
Earnings Call Timestamp End 1,747,062,000
Earnings Call Timestamp Start 1,747,062,000
Earnings Timestamp End 1,755,520,200
Earnings Timestamp Start 1,755,001,800
Ebitda -14,358,786
Ebitda Margins 0.0
Enterprise To Ebitda -0.306
Enterprise Value 4,388,274
Eps Current Year -3.11333
Eps Forward -2.8225
Eps Trailing Twelve Months -6.83
Esg Populated 0
Exchange NCM
Exchange Data Delayed By 0
Exchange Timezone Name America/New_York
Exchange Timezone Short Name EDT
Fifty Day Average 3.1124
Fifty Day Average Change -0.01240015
Fifty Day Average Change Percent -0.003984112
Fifty Two Week Change Percent -73.29588
Fifty Two Week High 41.217392
Fifty Two Week High Change -38.117393
Fifty Two Week High Change Percent -0.9247891
Fifty Two Week Low 2.52
Fifty Two Week Low Change 0.5799999
Fifty Two Week Low Change Percent 0.2301587
Fifty Two Week Range 2.52 - 41.217392
Financial Currency USD
First Trade Date Milliseconds 920,298,600,000
Float Shares 3,539,078
Forward Eps -2.8225
Forward P E -1.098317
Free Cashflow -8,529,147
Full Exchange Name NasdaqCM
Gmt Off Set Milliseconds -14,400,000
Gross Margins 0.0
Has Pre Post Market Data 1
Held Percent Insiders 0.00829
Held Percent Institutions 0.11016
Implied Shares Outstanding 3,922,764
Industry Biotechnology
Industry Disp Biotechnology
Industry Key biotechnology
Is Earnings Date Estimate 1
Language en-US
Last Fiscal Year End 1,767,139,200
Last Split Date 1,754,524,800
Last Split Factor 115:100
Long Business Summary Imunon, Inc., a clinical-stage biotechnology company, focuses on developing immunotherapies and vaccines. The company's lead clinical program is IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma. In addition, the company develops non-viral DNA technology across four modalities, such as TheraPlas for the coding of proteins and cytokines in the treatment of solid tumors; and PlaCCine for the coding of viral antigens that can elicit a strong immunological response. The company was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. The company was founded in 1982 and is headquartered in Lawrenceville, New Jersey.
Long Name Imunon, Inc.
Market us_market
Market Cap 12,160,568
Market State CLOSED
Max Age 86,400
Message Board Id finmb_260398
Most Recent Quarter 1,767,139,200
Name Change Date 2,026-04-18
Net Income To Common -14,495,028
Next Fiscal Year End 1,798,675,200
Non Diluted Market Cap 11,925,202
Number Of Analyst Opinions 4
Open 3.16
Operating Cashflow -13,896,624
Operating Margins 0.0
Payout Ratio 0.0
Peg Ratio 5.03
Phone 609 896 9100
Post Market Change 0.08000016
Post Market Change Percent 2.5806506
Post Market Price 3.18
Post Market Time 1,776,461,025
Prev Name Celsion Corporation
Previous Close 3.03
Price Eps Current Year -0.9957184
Price Hint 4
Price To Book 1.5012106
Profit Margins 0.0
Quick Ratio 1.899
Quote Source Name Nasdaq Real Time Price
Quote Type EQUITY
Recommendation Key none
Region US
Regular Market Change 0.0699999
Regular Market Change Percent 2.31023
Regular Market Day High 3.2
Regular Market Day Low 3.04
Regular Market Day Range 3.04 - 3.2
Regular Market Open 3.16
Regular Market Previous Close 3.03
Regular Market Price 3.1
Regular Market Time 1,776,456,001
Regular Market Volume 54,285
Return On Assets -0.83222
Return On Equity -2.56409
Sand P52 Week Change 0.38150132
Sector Healthcare
Sector Disp Healthcare
Sector Key healthcare
Shares Outstanding 3,922,764
Shares Percent Shares Out 0.0476
Shares Short 186,889
Shares Short Previous Month Date 1,772,150,400
Shares Short Prior Month 215,039
Short Name Imunon, Inc.
Short Percent Of Float 0.048
Short Ratio 0.98
Source Interval 15
State NJ
Symbol IMNN
Target High Price 33.0
Target Low Price 12.0
Target Mean Price 21.5
Target Median Price 20.5
Total Cash 8,781,059
Total Cash Per Share 2.238
Total Debt 1,008,765
Tradeable 0
Trailing Annual Dividend Rate 0.0
Trailing Annual Dividend Yield 0.0
Trailing Eps -6.83
Trailing Peg Ratio None
Triggerable 1
Two Hundred Day Average 4.6439824
Two Hundred Day Average Change -1.5439825
Two Hundred Day Average Change Percent -0.3324695
Type Disp Equity
Volume 54,285
Website https://imunon.com
Zip 8,648